Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply
Lancet Oncol
.
2021 Aug;22(8):e346.
doi: 10.1016/S1470-2045(21)00418-6.
Authors
Martin J van den Bent
1
,
Mircea Tesileanu
2
;
EORTC CATNON investigators
Affiliations
1
Erasmus MC Cancer Center, Brain Tumor Center, Rotterdam, 3008AE, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
2
Erasmus MC Cancer Center, Brain Tumor Center, Rotterdam, 3008AE, Netherlands.
PMID:
34339649
DOI:
10.1016/S1470-2045(21)00418-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Glioma* / drug therapy
Glioma* / genetics
Humans
Isocitrate Dehydrogenase
Temozolomide / adverse effects
Substances
Isocitrate Dehydrogenase
Temozolomide